Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow-up

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1082-1089

  Zander, A R ^a   Schmoor, C ^b   Kroger N ^a   Kruger W ^c   Mobus V ^d   Frickhofen, N ^e   Metzner, B ^f   Berdel, W E ^g   Koenigsmann, M ^h   Thiel, E ⁱ   Wandt, H ^j   Possinger, K ^k   Kreienberg, R ^l   Schumacher, M ^b   Jonat, W ^m  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d Department of Social Paediatrics   (Germany)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

^f KLINIKUM OLDENBURG   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Medical Hospital Nürnberg   (Germany)

^k HUMBOLDT UNIVERSITY   (Germany)

^l UNIVERSITY OF ULM   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Breast cancer; High risk; Randomized study

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; THIOTEPA;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 44849137163     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn023     Document Type: Article

References (41)

1. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
2. Peters WP, Berry D, Vredenburgh JJ et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 1995; 14: 317 (Abstr 933).
3. Gianni AM, Siena S, Bregni M et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: Five-year results. J Clin Oncol 1997; 15: 2312-2321.
4. Eddy D. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992; 10: 657-670.
5. Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med 1996; 125: 599-604.
6. Peters WP, Rosner G, Vredenburgh J et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/ SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 1999; 18: 1a.
7. Rodenhuis S, Richel DJ, van der Wall E et al. A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 1998; 352: 515-521.
8. Hortobagy GN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-233.
9. The Scandinavian Breast Cancer Study 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow-stem cells versus dose escalated and tailored FEC therapy, Proc Am Soc Clin Oncol 1999, 18: 2a.
10. Weiss RB, Rifkin RM, Stewart FM et al. High-dose chemotherapy for high-risk primary-breast cancer: An on-site review of the Bezwoda study. Lancet 2000; 355: 999-1003.
11. Rodenhuis S. The status high-dose chemotherapy in breast cancer. Oncologist 2000; 5: 369-375.
12. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114 - and NCIC MA-13. J Clin Oncol 2005; 23: 2191-2200.
13. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years follow-up. Ann Oncol 2002; 13: 689-698.
14. Gianni A, Bonadonna G. Five year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive lymph nodes. Proc Am Soc Clin Oncol 2001; 20: (Abstr 80).
15. Leonard RCF, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 2004; 96: 1076-1083.
16. Roche H, Viens P, Biron P et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-47.
17. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Cancer Group 9401 study. Lancet 2000; 356: 1384-1391.
18. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Netherlands Working Party on Autologous Transplantation Solid Tumors. N Engl J Med 2003; 349(1): 7-16.
19. Rodenhuis S, Bontenbal M, Beex LV et al. Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of Her2/neu-negative primary breast cancer: Update of the Dutch randomized trial. Proc Am Soc Clin Oncol 2005 (Abstr 672).
20. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349(1): 17-26.
21. Tokuda Y, Tajima T, Narabayashi M. Randomized phase 3 study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high- risk postoperative breast cancer: Japan Clinical Oncology (JCOG9208). Proceedings of ASCO 2001; 20: 38a (Abstr 148).
22. Zander AR, Kroger N, Schmoor C et al. High-dose chemotherapy with autologous stem-cell support compared with standard-dose chemotherapy in breast cancer patients-with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol, 2004; 22: 2273-2283.
23. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370-378.
24. Coombes RC, Howell A, Emson M et al, High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 2005; 16: 726-734.
25. Nitz UA, Mohmann S, Fischer J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-1944.
26. Hanrahan EO, Frye D, Buzdar AU et al: Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast cancer. Proc Am Soc Clin Oncol 2005 (Abstr 663).
27. Bearman SI, Green S, Gralow J et al. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with ≥ 4 involved axillary lymph nodes. Proc Am Soc Clin Oncol 2005 (Abstr 572).
28. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002; 359: 1309-1310.
29. SAS Institute Inc. SAS Language, Version 6. Cary, NC: SAS Institute Inc. 1990.
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley 1980.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
32. Cox DR. Regression models and life table (with discussion). J R Stat Soc B 1972; 34: 187-220.
33. Kroeger N, Milde-Langosch K, Riethdorf S et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006; 12(1): 159-168.
34. Schmoor C, Sauerbrei W, Bastert G et al. Long term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer 2001; 37: 1123-1131.
35. Linden HM, Haskell CM, Green SJ et al. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: Final analysis from INT-0137 (S9313). J Clin Oncol 2007; 25(6): 656-661.
36. Citron ML, Berry DA, Cirricione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21(8): 1431-1439.
37. Moore HC, Green SJ, Gralow JR et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 2007; 25(13): 1677-1682.
38. Zander AR, Kröger N. High-dose therapy for breast cancer - a case of suspended animation. Acta Haematol 2005; 114: 248-254.
39. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2005; 3: CD003142.
40. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
41. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002; 21: 3337-3351.